Tech stocks suffer worst week in nearly a year, driven down by war worries, Meta legal woes
Meta’s twin legal defeats this week and a big sell-off in Micron spurred a drop in technology stocks, which were broadly hit by rising oil prices.
China’s BYD sees first profit drop since 2021, even as the Tesla-rival takes global EV crown
BYD has been expanding into global markets including Latin America and Europe, where auto analysts say profit margins are higher than in China.
Epstein victims sue Google and the Trump administration over alleged disclosure of personal information
A lawsuit filed in Northern California alleges that Google’s AI features generated contact information for Epstein victims.
Beijing’s surprise intervention on Meta’s Manus rattles tech founders, VCs eyeing ‘China shedding’
Beijing’s review has fueled concerns and confusion among Chinese tech founders and investors that had quietly embraced the so-called “Singapore-washing” model.
Italy investigates Sephora and Benefit over skincare marketing to children
Italy’s competition authority said the LVMH-owned cosmetic brands Sephora and Benefit used an “insidious marketing strategy” to appeal to tween consumers.
1.4 million filers face tax refund delays amid IRS paper check phaseout
Many filers are facing tax refund delays amid the IRS push to phase out paper checks. Here’s what to know if you receive a CP53E notice.
Economist Nouriel Roubini: Trump is likely to escalate the Iran war — risking ‘1970s stagflation’
The economist and investor, known for calling the 2008 financial crisis, also said the “damage has already been done” to the economy.
Gulf markets are splintering as the Iran war continues. Here’s what to know
Investors are grappling with sharp divergence across the Gulf’s markets, as the Iran conflict drives asset volatility in the region.
Sony hikes PS5 prices by up to $150 citing ‘pressures’ in global economy
Sony, like other console makers, is contending with surging memory chip prices which have forced the company to raise prices.
AstraZeneca stock jumps after surprise trial win for lung disease drug where rivals have failed
The experimental drug reduced flare-ups for patients with chronic obstructive pulmonary disease, Astra said Friday.
